ELS Educational Services, Inc. Now Offers Vacation English Program at Two Additional Locations
PRINCETON, NJ, March 06, 2018 (GLOBE NEWSWIRE) -- ELS Educational Services, Inc. - one of the leading language services providers in the world - has added two new locations to its ELS Language Experience+ Vacation English program: San Diego, California and Boston, Massachusetts. Both locations will be offering the new Language Experience+ program starting in June 2018.
ELS Language Experience+ launched in January 2018 in Santa Monica, California, and Orlando, Florida, and will be available to students in the Manhattan, New York location starting March 2018.
The program allows students to develop their everyday English-speaking skills in a relaxed, customizable, and flexible learning environment. Students have the choice to study three or six hours per day and experience cultural and social activities specific to each location.
"We've received an extremely positive response from students with our Orlando and Santa Monica locations," said ELS COO Reiji Terasaka. "In addition to our New York location opening soon, ELS is delighted to expand this program to San Diego and Boston - this will give our students even more flexibility when it comes to their English training."
Located in downtown San Diego, students who sign up for ELS Language Experience+ at the San Diego Center will enjoy its close proximity to popular tourist destinations, shopping, entertainment, and the sandy white beaches and boardwalks of the Southern California coast.
ELS's Boston - Downtown Center is situated in the heart of historic downtown Boston, where students can enjoy the city's best food, shopping, entertainment, and sightseeing, including the famous Freedom Trail - home to 16 of the city's most historic sites - which begins just outside the downtown Center.
The ELS New York - Manhattan Center is adjacent to Battery Park in lower Manhattan, with views of the Statue of Liberty and the Hudson River, and immediate access to the subway, NYC buses, as well as the ferry to New Jersey. Visit famous landmarks like the Empire State Building, Broadway, Times Square, Fifth Avenue, Rockefeller Center, Central Park, Wall Street, and so much more!
To learn more about ELS Language Experience+ please visit: ELS.edu/landingpage/Language-Experience-Plus.
ELS Educational Services, Inc. offers more than 55 years of success in assisting international students-more than 1.2 million to date-achieve their personal and professional goals through English preparation and university study skills. ELS assists international students to identify and gain entry to higher education institutions around the world, including in Australia, Canada, India, Malaysia and the United States.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c654c99c-4ba2-4ee9-a7f6-129f6550f141
Carol Trinca-Bautista ELS Educational Services, Inc. 6097595582 CTrinca-Bautista@ELS.edu
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ELS Educational Services, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Code Pilot Launches Employer "Radar” Product, Makes Hiring Validated Technical Talent a Reality25.9.2018 21:25 | Pressemelding
Austin-Based Startup aims to offer hiring partners a meritocratic tool that is free from unconscious bias and puts the emphasis back on hard skills AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Code Pilot, a new data science platform, launched its “Radar” product today which enables companies to hire software engineers at scale with confidence and intelligence. The Bureau of Labor Statistics highlights that over 41 million people are searching and being recruited into jobs in the US every year. A massive issue in the current hiring landscape is exposed by the findings of Brandon Hall’s research brief that found a staggering 95 percent of employers surveyed admitted to making hiring mistakes by recruiting the wrong people each year. Code Pilot’s Radar aims to solve this issue by validating candidates and eliminating the noise often caused by cognitive bias. The Radar product has two distinct offerings: Test Manager uses advanced automation with a series of proprietary code assessmen
World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer25.9.2018 19:26 | Pressemelding
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years. PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy Recent
Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06 | Pressemelding
Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru
Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00 | Pressemelding
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00 | Pressemelding
Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr
Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00 | Pressemelding
First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom